ArticleLa Radiologia medica2026
Short-term monitoring of CFTR modulator therapy in adults and children with cystic fibrosis using low and ultra-low-dose lung CT.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith the advent of CFTR modulators for cystic fibrosis (CF) like Trikafta®, robust, radiation-sparing imaging strategies are urgently needed for monitoring therapeutic effects in both adult and pediatric patients. We investigated whether low-dose and ultra-low-dose lung CT could serve as innovative tool for short-term monitoring of treatment response in adults and children, respectively.
methodsA total of 30 CF patients (15 adults, 15 paediatric) initiated Trikafta® and underwent baseline CT and 12-18-month follow-up scans. Adults and children were imaged with low- and ultra-low-dose protocols, respectively. Disease severity and extent were quantified using Brody score through both qualitative and quantitative analysis. Pre- and post-treatment CT data were compared (paired t-tests), and results were correlated with spirometry and sweat chloride values.
resultsRemarkably, low and ultra-low-dose protocols maintained high diagnostic quality while reducing radiation exposure (effective dose 2.4 and 0.56 mSv respectively). The Brody score showed significant improvements across all patients, demonstrating substantial decreases in mucous plugging (73%) and bronchial thickening (51%). Each patient exhibited a drop in Brody score after therapy, paralleled by better lung function (r
conclusionsLow- and ultra-low-dose lung CT protocols represent an important advancement in cystic fibrosis imaging, providing sufficient detail to evaluate disease status while substantially reducing cumulative radiation exposure. By enabling reliable short-term assessment of CFTR modulator efficacy through established disease scoring systems, these protocols fill a critical gap in the routine follow-up of patients who require frequent imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.